Budesonide/salmeterol - Laboratoires SMB
Alternative Names: Budesonide/salmeterol xinafoate; Labazenit; Salmeterol/budesonideLatest Information Update: 27 Sep 2021
At a glance
- Originator Laboratoires SMB
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Glucocorticoids; Phenethylamines; Pregnenediones; Small molecules
- Mechanism of Action Arachidonic acid inhibitors; Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Asthma
Most Recent Events
- 24 Sep 2021 Phase-II development for Asthma (In children) is still ongoing in Bulgaria (Laboratoires SMB website, September 2021)
- 26 Apr 2021 Laboratoires SMB completes a phase I trial for Asthma (In children) in Bulgaria (Inhalation) (EudraCT2020-003404-14)
- 05 Apr 2021 Phase-II development is still ongoing for Asthma (In children) Bulgaria (Laboratoires SMB website, April 2021)